Novavax Inc Net Assets
Novavax Inc net assets. Based on the latest financial reports, Novavax Inc (NVAX) has net assets worth $-190.71 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($955.58 Million) and total liabilities ($1.15 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Novavax Inc (NVAX) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-190.71 Million |
| % of Total Assets | -19.96% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 238.42 |
Net Assets of Novavax Inc (1996–2025)
Net assets of Novavax Inc from 1996 to 2025. This chart illustrates how Novavax Inc's net assets have evolved over time, based on quarterly financial data. See Novavax Inc balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Novavax Inc (1996–2025)
The table below shows the annual net assets of Novavax Inc from 1996 to 2025. For live market cap and overall valuation, see NVAX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-127.75 Million | +79.52% |
| 2024-12-31 | $-623.84 Million | +12.98% |
| 2023-12-31 | $-716.93 Million | -13.07% |
| 2022-12-31 | $-634.08 Million | -80.30% |
| 2021-12-31 | $-351.67 Million | -156.07% |
| 2020-12-31 | $627.21 Million | +437.18% |
| 2019-12-31 | $-186.02 Million | -10.77% |
| 2018-12-31 | $-167.94 Million | -65.08% |
| 2017-12-31 | $-101.73 Million | -1734.33% |
| 2016-12-31 | $-5.55 Million | -101.89% |
| 2015-12-31 | $292.67 Million | +27.46% |
| 2014-12-31 | $229.62 Million | +12.98% |
| 2013-12-31 | $203.23 Million | +153.28% |
| 2012-12-31 | $80.24 Million | +49.01% |
| 2011-12-31 | $53.85 Million | -8.81% |
| 2010-12-31 | $59.05 Million | -20.70% |
| 2009-12-31 | $74.47 Million | +63.70% |
| 2008-12-31 | $45.49 Million | -27.87% |
| 2007-12-31 | $63.06 Million | -32.91% |
| 2006-12-31 | $94.00 Million | +89.32% |
| 2005-12-31 | $49.65 Million | +49.19% |
| 2004-12-31 | $33.28 Million | -7.41% |
| 2003-12-31 | $35.94 Million | +345.24% |
| 2002-12-31 | $8.07 Million | -70.64% |
| 2001-12-31 | $27.49 Million | -13.61% |
| 2000-12-31 | $31.82 Million | +1036.57% |
| 1999-12-31 | $2.80 Million | -6.67% |
| 1998-12-31 | $3.00 Million | -53.85% |
| 1997-12-31 | $6.50 Million | +27.45% |
| 1996-12-31 | $5.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Novavax Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 454134800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Novavax Inc Net Assets Breakdown (December 2025)
Novavax Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.65 Million | % |
| Other Comprehensive Income | $2.01 Million | % |
| Other Components | $4.44 Billion | % |
| Total Equity | $-127.75 Million | 100.00% |
Novavax Inc Competitors by Market Cap
The table below lists competitors of Novavax Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AeroSpace Technology of Korea
KQ:067390
|
$1.31 Billion |
|
Gansu Guofang Gongmao(Grp)
SHG:601086
|
$1.31 Billion |
|
Ganzhou Tengyuan Cobalt New Material Co. Ltd.
SHE:301219
|
$1.31 Billion |
|
Zhejiang Huatie Constr Safety
SHG:603300
|
$1.31 Billion |
|
Grupo Nacional Provincial S.A.B
MX:GNP
|
$1.31 Billion |
|
Grupo Aeroméxico S.A.B. de C.V
MX:AEROMEX
|
$1.31 Billion |
|
Couchbase Inc
NASDAQ:BASE
|
$1.31 Billion |
|
Xiamen Meiya Pico Information
SHE:300188
|
$1.31 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Novavax Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -623,841,000 to -127,753,000, a change of 496,088,000.
- Net income of 440,302,000 contributed positively to equity growth.
- Share repurchases of 4,798,000 reduced equity.
- Other comprehensive income increased equity by 24,569,000.
- Other factors increased equity by 36,015,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $440.30 Million | +344.65% |
| Share Repurchases | $4.80 Million | -3.76% |
| Other Comprehensive Income | $24.57 Million | +19.23% |
| Other Changes | $36.02 Million | +28.19% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Novavax Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $10.07 | $9.53 | x |
| 1997-12-31 | $11.14 | $9.53 | x |
| 1998-12-31 | $4.83 | $9.53 | x |
| 1999-12-31 | $3.86 | $9.53 | x |
| 2000-12-31 | $33.47 | $9.53 | x |
| 2001-12-31 | $24.25 | $9.53 | x |
| 2002-12-31 | $6.61 | $9.53 | x |
| 2003-12-31 | $24.08 | $9.53 | x |
| 2004-12-31 | $18.03 | $9.53 | x |
| 2005-12-31 | $23.22 | $9.53 | x |
| 2006-12-31 | $32.05 | $9.53 | x |
| 2007-12-31 | $20.64 | $9.53 | x |
| 2008-12-31 | $13.34 | $9.53 | x |
| 2009-12-31 | $17.41 | $9.53 | x |
| 2010-12-31 | $11.27 | $9.53 | x |
| 2011-12-31 | $9.48 | $9.53 | x |
| 2012-12-31 | $12.18 | $9.53 | x |
| 2013-12-31 | $23.96 | $9.53 | x |
| 2014-12-31 | $20.33 | $9.53 | x |
| 2015-12-31 | $22.32 | $9.53 | x |
| 2016-12-31 | $-0.41 | $9.53 | x |
| 2017-12-31 | $-6.95 | $9.53 | x |
| 2018-12-31 | $-9.08 | $9.53 | x |
| 2019-12-31 | $-7.72 | $9.53 | x |
| 2020-12-31 | $10.90 | $9.53 | x |
| 2021-12-31 | $-4.73 | $9.53 | x |
| 2022-12-31 | $-8.11 | $9.53 | x |
| 2023-12-31 | $-7.11 | $9.53 | x |
| 2024-12-31 | $-4.10 | $9.53 | x |
| 2025-12-31 | $-0.74 | $9.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Novavax Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 39.19%
- • Asset Turnover: 0.95x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-50.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -107.84% | -5500.00% | 0.02x | 1.12x | $-6.01 Million |
| 1997 | -69.23% | -900.00% | 0.07x | 1.05x | $-5.15 Million |
| 1998 | -160.00% | -685.71% | 0.18x | 1.27x | $-5.10 Million |
| 1999 | -160.71% | -375.00% | 0.27x | 1.61x | $-4.78 Million |
| 2000 | -38.31% | -492.57% | 0.04x | 1.78x | $-15.37 Million |
| 2001 | -35.45% | -40.49% | 0.36x | 2.44x | $-12.49 Million |
| 2002 | -281.15% | -151.26% | 0.26x | 7.12x | $-23.50 Million |
| 2003 | -48.06% | -146.57% | 0.14x | 2.34x | $-20.87 Million |
| 2004 | -77.88% | -313.80% | 0.11x | 2.34x | $-29.25 Million |
| 2005 | -22.50% | -151.25% | 0.09x | 1.70x | $-16.14 Million |
| 2006 | -24.54% | -492.59% | 0.04x | 1.30x | $-32.47 Million |
| 2007 | -55.13% | -2297.75% | 0.02x | 1.45x | $-41.07 Million |
| 2008 | -79.25% | -3388.06% | 0.01x | 1.68x | $-40.60 Million |
| 2009 | -51.53% | -11807.38% | 0.00x | 1.15x | $-45.82 Million |
| 2010 | -60.47% | -10410.50% | 0.00x | 1.27x | $-41.61 Million |
| 2011 | -35.96% | -131.84% | 0.22x | 1.24x | $-24.75 Million |
| 2012 | -35.53% | -129.13% | 0.22x | 1.28x | $-36.53 Million |
| 2013 | -25.58% | -248.54% | 0.09x | 1.16x | $-72.31 Million |
| 2014 | -36.12% | -270.55% | 0.11x | 1.20x | $-105.91 Million |
| 2015 | -53.62% | -432.93% | 0.09x | 1.32x | $-186.20 Million |
| 2016 | 0.00% | -1823.53% | 0.04x | 0.00x | $-279.41 Million |
| 2017 | 0.00% | -589.46% | 0.10x | 0.00x | $-173.60 Million |
| 2018 | 0.00% | -538.81% | 0.16x | 0.00x | $-167.95 Million |
| 2019 | 0.00% | -697.15% | 0.11x | 0.00x | $-111.50 Million |
| 2020 | -68.16% | -89.89% | 0.30x | 2.52x | $-490.23 Million |
| 2021 | 0.00% | -152.12% | 0.44x | 0.00x | $-1.71 Billion |
| 2022 | 0.00% | -41.15% | 0.71x | 0.00x | $-594.53 Million |
| 2023 | 0.00% | -97.97% | 0.31x | 0.00x | $-473.37 Million |
| 2024 | 0.00% | -27.49% | 0.44x | 0.00x | $-125.11 Million |
| 2025 | 0.00% | 39.19% | 0.95x | 0.00x | $453.08 Million |
Industry Comparison
This section compares Novavax Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $186,602,403
- Average return on equity (ROE) among peers: -32.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Novavax Inc (NVAX) | $-190.71 Million | -107.84% | N/A | $1.31 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $26.13 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.61 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $17.31 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $792.42 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $26.12 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $7.41 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $479.08 Million | -51.18% | 0.13x | $3.53 Billion |
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more